Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies

1.

Ragnhammar, P., Hafstrom, L., Nygren, P., & Glimelius, B. (2001). A systematic overview of chemotherapy effects in colorectal cancer. [Review]. Acta Oncologica, 40(2-3), 282–308.PubMedCrossRef

2.

Balar, A. V., & Milowsky, M. I. (2015). Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough? [Review]. Cancer, 121(2), 179–187. https://doi.org/10.1002/cncr.28754.PubMedCrossRef

3.

Ludwig, J. A., & Weinstein, J. N. (2005). Biomarkers in cancer staging, prognosis and treatment selection. [Research Support, N.I.H., Extramural. Research Support, N.I.H., Intramural. Research Support, Non-U.S. Gov’t. Review]. Nature Reviews. Cancer, 5(11), 845–856. https://doi.org/10.1038/nrc1739.PubMedCrossRef

4.

Drucker, E., & Krapfenbauer, K. (2013). Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. The EPMA Journal, 4(1), 7. https://doi.org/10.1186/1878-5085-4-7.PubMedPubMedCentralCrossRef

5.

Panneerselvam, J., Xie, G., Che, R., Su, M., Zhang, J., Jia, W., et al. (2016). Distinct metabolic signature of human bladder cancer cells carrying an impaired fanconi anemia tumor-suppressor signaling pathway. [Research Support, N.I.H., Extramural]. Journal of Proteome Research, 15(4), 1333–1341. https://doi.org/10.1021/acs.jproteome.6b00076. PubMedPubMedCentralCrossRef

6.

Halama, A., Guerrouahen, B. S., Pasquier, J., Diboun, I., Karoly, E. D., Suhre, K., et al. (2015). Metabolic signatures differentiate ovarian from colon cancer cell lines. [Research Support, Non-U.S. Gov’t]. Journal of Translational Medicine, 13, 223. https://doi.org/10.1186/s12967-015-0576-z. PubMedPubMedCentralCrossRef

7.

Zhang, A., Sun, H., Yan, G., Wang, P., & Wang, X. (2015, 2015). Metabolomics for biomarker discovery: moving to the clinic. [Research Support, Non-U.S. Gov’t. Review]. BioMed Research International, 354671. https://doi.org/10.1155/2015/354671.

8.

Mal, M. (2016). Noninvasive metabolic profiling for painless diagnosis of human diseases and disorders. [Review]. Future Science OA, 2(2), FSO106. https://doi.org/10.4155/fsoa-2015-0014.PubMedPubMedCentralCrossRef

9.

Louis, E., Adriaensens, P., Guedens, W., Bigirumurame, T., Baeten, K., Vanhove, K., et al. (2016). Detection of lung cancer through metabolic changes measured in blood plasma. Journal of Thoracic Oncology, 11(4), 516–523. https://doi.org/10.1016/j.jtho.2016.01.011.PubMedCrossRef

10.

Gold, P., & Freedman, S. O. (1965). Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. The Journal of Experimental Medicine, 121, 439–462.PubMedPubMedCentralCrossRef

11.

Chatterjee, S. K., & Zetter, B. R. (2005). Cancer biomarkers: knowing the present and predicting the future. [Review]. Future Oncology, 1(1), 37–50. https://doi.org/10.1517/14796694.1.1.37.PubMedCrossRef

12.

Tanaka, T., Tanaka, M., & Ishigamori, R. (2010). Biomarkers for colorectal cancer. [Research Support, Non-U.S. Gov’t Review]. International Journal of Molecular Sciences, 11(9), 3209–3225. https://doi.org/10.3390/ijms11093209.PubMedPubMedCentralCrossRef

13.

Grunnet, M., & Sorensen, J. B. (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. [Review]. Lung Cancer, 76(2), 138–143. https://doi.org/10.1016/j.lungcan.2011.11.012.PubMedCrossRef

14.

Jakupciak, J. P., Wang, W., Markowitz, M. E., Ally, D., Coble, M., Srivastava, S., et al. (2005). Mitochondrial DNA as a cancer biomarker. [Comparative Study Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.] The Journal of Molecular Diagnostics, 7(2), 258–267. https://doi.org/10.1016/S1525-1578(10)60553-3. PubMedPubMedCentralCrossRef

15.

Cai, F. F., Kohler, C., Zhang, B., Chen, W. J., Barekati, Z., Garritsen, H. S., et al. (2011). Mutations of mitochondrial DNA as potential biomarkers in breast cancer. [Research Support, Non-U.S. Gov’t]. Anticancer Research, 31(12), 4267–4271.PubMed

16.

Vincent, M. D., Kuruvilla, M. S., Leighl, N. B., & Kamel-Reid, S. (2012). Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Current Oncology, 19(Suppl 1), S33–S44. https://doi.org/10.3747/co.19.1149.PubMedPubMedCentral

17.

Punt, C. J., Koopman, M., & Vermeulen, L. (2016). From tumour heterogeneity to advances in precision treatment of colorectal cancer. [Review]. Nature Reviews. Clinical Oncology. https://doi.org/10.1038/nrclinonc.2016.171.

18.

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nature Reviews. Cancer, 7(3), 169–181. https://doi.org/10.1038/nrc2088.PubMedCrossRef

19.

Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., et al. (2012). Prognostic and predictive roles of KRAS mutation in colorectal cancer. [Review]. International Journal of Molecular Sciences, 13(10), 12153–12168. https://doi.org/10.3390/ijms131012153. PubMedPubMedCentralCrossRef

20.

Tomasini, P., Serdjebi, C., Khobta, N., Metellus, P., Ouafik, L., Nanni, I., et al. (2016). EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer. International Journal of Molecular Sciences, 17(12). https://doi.org/10.3390/ijms17122132.

21.

Lohinai, Z., Klikovits, T., Moldvay, J., Ostoros, G., Raso, E., Timar, J., et al. (2017). KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Scientific Reports, 7, 39721. https://doi.org/10.1038/srep39721.PubMedPubMedCentralCrossRef

22.

Ma, C., Wei, S., & Song, Y. (2011). T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. Journal of Thoracic Disease, 3(1), 10–18. https://doi.org/10.3978/j.issn.2072-1439.2010.12.02.PubMedPubMedCentral

23.

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991). p53 mutations in human cancers. [Comparative Study Research Support, U.S. Gov’t, P.H.S. Review]. Science, 253(5015), 49–53.PubMedCrossRef

24.

Moller, M. B., Gerdes, A. M., Skjodt, K., Mortensen, L. S., & Pedersen, N. T. (1999). Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin’s lymphoma. [Comparative Study Research Support, Non-U.S. Gov’t]. Clinical Cancer Research, 5(5), 1085–1091.PubMed

25.

Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review]. Oncogene, 22(47), 7265–7279. https://doi.org/10.1038/sj.onc.1206933. PubMedCrossRef

26.

Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C., & Lahav, G. (2016). Cell-to-cell variation in p53 dynamics leads to fractional killing. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Cell, 165(3), 631–642. https://doi.org/10.1016/j.cell.2016.03.025.PubMedPubMedCentralCrossRef

27.

Zhao, R., Choi, B. Y., Lee, M. H., Bode, A. M., & Dong, Z. (2016). Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. [Review]. eBioMedicine, 8, 30–39. https://doi.org/10.1016/j.ebiom.2016.04.017.PubMedPubMedCentralCrossRef

28.

Zhao, J., Zhang, Z., Liao, Y., & Du, W. (2014). Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death. American Journal of Cancer Research, 4(1), 42–52.PubMedPubMedCentral

29.

Theriault, B. L., Dimaras, H., Gallie, B. L., & Corson, T. W. (2014). The genomic landscape of retinoblastoma: a review. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Clinical and Experimental Ophthalmology, 42(1), 33–52. https://doi.org/10.1111/ceo.12132.PubMedCrossRef

30.

Sonnenblick, A., de Azambuja, E., Azim Jr., H. A., & Piccart, M. (2015). An update on PARP inhibitors--moving to the adjuvant setting. [Review]. Nature Reviews. Clinical Oncology, 12(1), 27–41. https://doi.org/10.1038/nrclinonc.2014.163.PubMedCrossRef

31.

Ledermann, J. A. (2016). PARP inhibitors in ovarian cancer. Annals of Oncology, 27(Suppl 1), i40–i44. https://doi.org/10.1093/annonc/mdw094.PubMedCrossRef

32.

Dawson, M. A., & Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell, 150(1), 12–27. https://doi.org/10.1016/j.cell.2012.06.013.PubMedCrossRef

33.

Ashktorab, H., Rahi, H., Wansley, D., Varma, S., Shokrani, B., Lee, E., et al. (2013). Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics, 8(8), 807–815. https://doi.org/10.4161/epi.25497.PubMedPubMedCentralCrossRef

34.

Szmida, E., Karpinski, P., Leszczynski, P., Sedziak, T., Kielan, W., Ostasiewicz, P., et al. (2015). Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer. Journal of Applied Genetics, 56(2), 185–192. https://doi.org/10.1007/s13353-014-0253-6.PubMedCrossRef

35.

Warren, J. D., Xiong, W., Bunker, A. M., Vaughn, C. P., Furtado, L. V., Roberts, W. L., et al. (2011). Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Medicine, 9, 133. https://doi.org/10.1186/1741-7015-9-133.PubMedPubMedCentralCrossRef

36.

Boland, C. R., & Goel, A. (2010). Microsatellite instability in colorectal cancer. Gastroenterology, 138(6), 2073–2087 e2073. https://doi.org/10.1053/j.gastro.2009.12.064.PubMedPubMedCentralCrossRef

37.

Herceg, Z., & Hainaut, P. (2007). Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. [Review]. Molecular Oncology, 1(1), 26–41. https://doi.org/10.1016/j.molonc.2007.01.004.PubMedPubMedCentralCrossRef

38.

Gatalica, Z., Vranic, S., Xiu, J., Swensen, J., & Reddy, S. (2016). High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer, 15(3), 405–412. https://doi.org/10.1007/s10689-016-9884-6.PubMedPubMedCentralCrossRef

39.

Des Guetz, G., Schischmanoff, O., Nicolas, P., Perret, G. Y., Morere, J. F., & Uzzan, B. (2009). Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. [Meta-Analysis Review]. European Journal of Cancer, 45(10), 1890–1896. https://doi.org/10.1016/j.ejca.2009.04.018.PubMedCrossRef

40.

Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., et al. (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] The New England Journal of Medicine, 349(3), 247–257. https://doi.org/10.1056/NEJMoa022289. PubMedPubMedCentralCrossRef

41.

Koopman, M., Venderbosch, S., van Tinteren, H., Ligtenberg, M. J., Nagtegaal, I., Van Krieken, J. H., et al. (2009). Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. European Journal of Cancer, 45(11), 1999–2006. https://doi.org/10.1016/j.ejca.2009.04.017.PubMedCrossRef

42.

Devaud, N., & Gallinger, S. (2013). Chemotherapy of MMR-deficient colorectal cancer. [Review]. Familial Cancer, 12(2), 301–306. https://doi.org/10.1007/s10689-013-9633-z.PubMedCrossRef

43.

Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016). Classification and characterization of microsatellite instability across 18 cancer types. Nature Medicine, 22(11), 1342–1350. https://doi.org/10.1038/nm.4191.PubMedCrossRef

44.

Jeronimo, C., Usadel, H., Henrique, R., Oliveira, J., Lopes, C., Nelson, W. G., et al. (2001). Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] Journal of the National Cancer Institute, 93(22), 1747–1752.PubMedCrossRef

45.

Gonzalgo, M. L., Pavlovich, C. P., Lee, S. M., & Nelson, W. G. (2003). Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov’t, P.H.S.] Clinical Cancer Research, 9(7), 2673–2677.PubMed

46.

Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., et al. (2010). MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. [Research Support, N.I.H., Extramural]. Neuro-Oncology, 12(2), 116–121. https://doi.org/10.1093/neuonc/nop020. PubMedCrossRef

47.

Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., et al. (2005). Global histone modification patterns predict risk of prostate cancer recurrence. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] Nature, 435(7046), 1262–1266. https://doi.org/10.1038/nature03672. PubMedCrossRef

48.

Seligson, D. B., Horvath, S., McBrian, M. A., Mah, V., Yu, H., Tze, S., et al. (2009). Global levels of histone modifications predict prognosis in different cancers. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. The American Journal of Pathology, 174(5), 1619–1628. https://doi.org/10.2353/ajpath.2009.080874. PubMedPubMedCentralCrossRef

49.

Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., et al. (2005). Detection and quantification of mutations in the plasma of patients with colorectal tumors. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Proceedings of the National Academy of Sciences of the United States of America, 102(45), 16368–16373. https://doi.org/10.1073/pnas.0507904102. PubMedPubMedCentralCrossRef

50.

Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D., et al. (2001). DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. [Research Support, Non-U.S. Gov’t]. Cancer Research, 61(4), 1659–1665.PubMed

51.

Spindler, K. L., Pallisgaard, N., Andersen, R. F., Brandslund, I., & Jakobsen, A. (2015). Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. [Clinical Trial, Phase II Research Support, Non-U.S. Gov’t]. PLoS One, 10(4), e0108247. https://doi.org/10.1371/journal.pone.0108247.PubMedPubMedCentralCrossRef

52.

Schwarzenbach, H., & Pantel, K. (2015). Circulating DNA as biomarker in breast cancer. [Research Support, Non-U.S. Gov’t Review]. Breast Cancer Res, 17(1), 136. https://doi.org/10.1186/s13058-015-0645-5.PubMedPubMedCentralCrossRef

53.

No, J. H., Kim, K., Park, K. H., & Kim, Y. B. (2012). Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. [Research Support, Non-U.S. Gov’t]. Anticancer Research, 32(8), 3467–3471.PubMed

54.

Szpechcinski, A., Chorostowska-Wynimko, J., Struniawski, R., Kupis, W., Rudzinski, P., Langfort, R., et al. (2015). Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. [Evaluation Studies Research Support, Non-U.S. Gov’t]. British Journal of Cancer, 113(3), 476–483. https://doi.org/10.1038/bjc.2015.225. PubMedPubMedCentralCrossRef

55.

Spindler, K. L., Appelt, A. L., Pallisgaard, N., Andersen, R. F., Brandslund, I., & Jakobsen, A. (2014). Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. International Journal of Cancer, 135(12), 2984–2991. https://doi.org/10.1002/ijc.28946.PubMedCrossRef

56.

Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., et al. (2013). Signatures of mutational processes in human cancer. [Research Support, Non-U.S. Gov’t]. Nature, 500(7463), 415–421. https://doi.org/10.1038/nature12477. PubMedPubMedCentralCrossRef

57.

Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016). Translating RNA sequencing into clinical diagnostics: opportunities and challenges. [Research Support, Non-U.S. Gov’t Review]. Nature Reviews. Genetics, 17(5), 257–271. https://doi.org/10.1038/nrg.2016.10.PubMedCrossRef

58.

Peng, L., Bian, X. W., Li, D. K., Xu, C., Wang, G. M., Xia, Q. Y., et al. (2015). Large-scale RNA-Seq transcriptome analysis of 4043 cancers and 548 normal tissue controls across 12 TCGA cancer types. [Research Support, Non-U.S. Gov’t]. Scientific Reports, 5, 13413. https://doi.org/10.1038/srep13413. PubMedPubMedCentralCrossRef

59.

Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J., & Stratton, M. R. (2013). Deciphering signatures of mutational processes operative in human cancer. [Research Support, Non-U.S. Gov’t]. Cell Reports, 3(1), 246–259. https://doi.org/10.1016/j.celrep.2012.12.008.PubMedPubMedCentralCrossRef

60.

Silveyra, P., Wang, G., & Floros, J. (2010). Human SP-A1 (SFTPA1) variant-specific 3′ UTRs and poly(A) tail differentially affect the in vitro translation of a reporter gene. [Research Support, N.I.H., Extramural]. American Journal of Physiology. Lung Cellular and Molecular Physiology, 299(4), L523–L534. https://doi.org/10.1152/ajplung.00113.2010.PubMedPubMedCentralCrossRef

61.

Gray, J. W., & Collins, C. (2000). Genome changes and gene expression in human solid tumors. [Review]. Carcinogenesis, 21(3), 443–452.PubMedCrossRef

62.

Velculescu, V. E., Zhang, L., Vogelstein, B., & Kinzler, K. W. (1995). Serial analysis of gene expression. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] Science, 270(5235), 484–487.PubMedCrossRef

63.

Peck, D., Crawford, E. D., Ross, K. N., Stegmaier, K., Golub, T. R., & Lamb, J. (2006). A method for high-throughput gene expression signature analysis. [Research Support, Non-U.S. Gov’t]. Genome Biol, 7(7), R61. https://doi.org/10.1186/gb-2006-7-7-r61.PubMedPubMedCentralCrossRef

64.

Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., et al. (2015). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26(Suppl 5), v8–30. https://doi.org/10.1093/annonc/mdv298.PubMedCrossRef

65.

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., et al. (2015). Prospective validation of a 21-gene expression assay in breast cancer. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Validation Studies]. The New England Journal of Medicine, 373(21), 2005–2014. https://doi.org/10.1056/NEJMoa1510764.PubMedPubMedCentralCrossRef

66.

Salazar, R., Roepman, P., Capella, G., Moreno, V., Simon, I., Dreezen, C., et al. (2011). Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. Journal of Clinical Oncology, 29(1), 17–24. https://doi.org/10.1200/JCO.2010.30.1077.PubMedCrossRef

67.

Gamazon, E. R., & Stranger, B. E. (2014). Genomics of alternative splicing: evolution, development and pathophysiology. [Review]. Human Genetics, 133(6), 679–687. https://doi.org/10.1007/s00439-013-1411-3.PubMedCrossRef

68.

Pajares, M. J., Ezponda, T., Catena, R., Calvo, A., Pio, R., & Montuenga, L. M. (2007). Alternative splicing: an emerging topic in molecular and clinical oncology. [Research Support, Non-U.S. Gov’t Review]. The Lancet Oncology, 8(4), 349–357. https://doi.org/10.1016/S1470-2045(07)70104-3.PubMedCrossRef

69.

Qu, Y., Dai, B., Ye, D., Kong, Y., Chang, K., Jia, Z., et al. (2015). Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. [Research Support, Non-U.S. Gov’t]. Scientific Reports, 5, 7654. https://doi.org/10.1038/srep07654. PubMedPubMedCentralCrossRef

70.

Gan, H. K., Cvrljevic, A. N., & Johns, T. G. (2013). The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. [Research Support, Non-U.S. Gov’t Review]. The FEBS Journal, 280(21), 5350–5370. https://doi.org/10.1111/febs.12393.PubMedCrossRef

71.

Zhou, M., Zhong, L., Xu, W., Sun, Y., Zhang, Z., Zhao, H., et al. (2016). Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients. Scientific Reports, 6, 31038. https://doi.org/10.1038/srep31038.PubMedPubMedCentralCrossRef

72.

Prensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., et al. (2014). RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. [Comparative Study Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov’t, Non-P.H.S.] The Lancet Oncology, 15(13), 1469–1480. https://doi.org/10.1016/S1470-2045(14)71113-1. PubMedPubMedCentralCrossRef

73.

de Kok, J. B., Verhaegh, G. W., Roelofs, R. W., Hessels, D., Kiemeney, L. A., Aalders, T. W., et al. (2002). DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Research, 62(9), 2695–2698.PubMed

74.

Bussemakers, M. J., van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F., Schalken, J. A., et al. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. [Research Support, Non-U.S. Gov’t]. Cancer Research, 59(23), 5975–5979.PubMed

75.

Luo, X., Burwinkel, B., Tao, S., & Brenner, H. (2011). MicroRNA signatures: novel biomarker for colorectal cancer? [Review]. Cancer Epidemiology, Biomarkers & Prevention, 20(7), 1272–1286. https://doi.org/10.1158/1055-9965.EPI-11-0035.CrossRef

76.

Kelly, B. D., Miller, N., Sweeney, K. J., Durkan, G. C., Rogers, E., Walsh, K., et al. (2015). A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. Journal of Clinical Medicine , 4(7), 1369–1379. https://doi.org/10.3390/jcm4071369.PubMedPubMedCentralCrossRef

77.

Li, X., Shi, Y., Yin, Z., Xue, X., & Zhou, B. (2014). An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma. [Research Support, Non-U.S. Gov’t]. Journal of Translational Medicine, 12, 159. https://doi.org/10.1186/1479-5876-12-159.PubMedPubMedCentralCrossRef

78.

Ouyang, L., Liu, P., Yang, S., Ye, S., Xu, W., & Liu, X. (2013). A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Medical Oncology, 30(1), 340. https://doi.org/10.1007/s12032-012-0340-7.PubMedCrossRef

79.

Macha, M. A., Seshacharyulu, P., Krishn, S. R., Pai, P., Rachagani, S., Jain, M., et al. (2014). MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. [Research Support, N.I.H., Extramural Review]. Current Pharmaceutical Design, 20(33), 5287–5297.PubMedPubMedCentralCrossRef

80.

Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Proceedings of the National Academy of Sciences of the United States of America, 105(30), 10513–10518. https://doi.org/10.1073/pnas.0804549105. PubMedPubMedCentralCrossRef

81.

Brase, J. C., Johannes, M., Schlomm, T., Falth, M., Haese, A., Steuber, T., et al. (2011). Circulating miRNAs are correlated with tumor progression in prostate cancer. [Research Support, Non-U.S. Gov’t]. International Journal of Cancer, 128(3), 608–616. https://doi.org/10.1002/ijc.25376. PubMedCrossRef

82.

Cummins, J. M., He, Y., Leary, R. J., Pagliarini, R., Diaz Jr., L. A., Sjoblom, T., et al. (2006). The colorectal microRNAome. Proceedings of the National Academy of Sciences of the United States of America, 103(10), 3687–3692. https://doi.org/10.1073/pnas.0511155103.PubMedPubMedCentralCrossRef

83.

Liu, G. H., Zhou, Z. G., Chen, R., Wang, M. J., Zhou, B., Li, Y., et al. (2013). Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biology, 34(4), 2175–2181. https://doi.org/10.1007/s13277-013-0753-8.PubMedCrossRef

84.

Giraldez, M. D., Lozano, J. J., Ramirez, G., Hijona, E., Bujanda, L., Castells, A., et al. (2013). Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clinical Gastroenterology and Hepatology, 11(6), 681–688 e683. https://doi.org/10.1016/j.cgh.2012.12.009.PubMedCrossRef

85.

Chen, Q., Xia, H. W., Ge, X. J., Zhang, Y. C., Tang, Q. L., & Bi, F. (2013). Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pacific Journal of Cancer Prevention, 14(12), 7421–7426.PubMedCrossRef

86.

Bradley, B. P., Shrader, E. A., Kimmel, D. G., & Meiller, J. C. (2002). Protein expression signatures: an application of proteomics. Marine Environmental Research, 54(3-5), 373–377.PubMedCrossRef

87.

Guimaraes, J. C., & Zavolan, M. (2016). Patterns of ribosomal protein expression specify normal and malignant human cells. Genome Biology, 17(1), 236. https://doi.org/10.1186/s13059-016-1104-z.PubMedPubMedCentralCrossRef

88.

Myers, M. V., Manning, H. C., Coffey, R. J., & Liebler, D. C. (2012). Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling. [Research Support, N.I.H., Extramural]. Molecular and Cellular Probes, 11(2), M111 015222. https://doi.org/10.1074/mcp.M111.015222.CrossRef

89.

Weigel, M. T., & Dowsett, M. (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. [Research Support, Non-U.S. Gov’t Review]. Endocrine-Related Cancer, 17(4), R245–R262. https://doi.org/10.1677/ERC-10-0136.PubMedCrossRef

90.

Dai, X., Xiang, L., Li, T., & Bai, Z. (2016). Cancer hallmarks, biomarkers and breast cancer molecular subtypes. [Review]. Journal of Cancer, 7(10), 1281–1294. https://doi.org/10.7150/jca.13141.PubMedPubMedCentralCrossRef

91.

Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W. L., et al. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.] Cancer Cell, 10(6), 529–541. https://doi.org/10.1016/j.ccr.2006.10.009. PubMedCrossRef

92.

Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., et al. (2005). Identification of molecular apocrine breast tumours by microarray analysis. [Research Support, Non-U.S. Gov’t]. Oncogene, 24(29), 4660–4671. https://doi.org/10.1038/sj.onc.1208561. PubMedCrossRef

93.

Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2010). Combinatorial biomarker expression in breast cancer. [Research Support, Non-U.S. Gov’t Review]. Breast Cancer Research and Treatment, 120(2), 293–308. https://doi.org/10.1007/s10549-010-0746-x.PubMedCrossRef

94.

Ogawa, Y., Hai, E., Matsumoto, K., Ikeda, K., Tokunaga, S., Nagahara, H., et al. (2008). Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. [Research Support, Non-U.S. Gov’t]. International Journal of Clinical Oncology, 13(5), 431–435. https://doi.org/10.1007/s10147-008-0770-6. PubMedCrossRef

95.

Viale, G., Giobbie-Hurder, A., Regan, M. M., Coates, A. S., Mastropasqua, M. G., Dell’Orto, P., et al. (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. [Clinical Trial Clinical Trial, Phase III Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of Clinical Medicine , 26(34), 5569–5575. https://doi.org/10.1200/JCO.2008.17.0829.

96.

Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., et al. (2011). Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. [Clinical Trial, Phase III Comparative Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.] Journal of Clinical Oncology, 29(7), 859–867. https://doi.org/10.1200/JCO.2009.27.5644. PubMedCrossRef

97.

Maris, P., Blomme, A., Palacios, A. P., Costanza, B., Bellahcene, A., Bianchi, E., et al. (2015). Asporin is a fibroblast-derived TGF-beta1 inhibitor and a tumor suppressor associated with good prognosis in breast cancer. [Research Support, Non-U.S. Gov’t]. PLoS Medicine, 12(9), e1001871. https://doi.org/10.1371/journal.pmed.1001871.PubMedPubMedCentralCrossRef

98.

Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012). Beyond PSA: the next generation of prostate cancer biomarkers. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Review]. Science Translational Medicine, 4(127), 127rv123. https://doi.org/10.1126/scitranslmed.3003180.CrossRef

99.

Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. [Review]. Nature Reviews. Cancer, 8(4), 268–278. https://doi.org/10.1038/nrc2351.PubMedCrossRef

100.

Balk, S. P., Ko, Y. J., & Bubley, G. J. (2003). Biology of prostate-specific antigen. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. Review]. Journal of Clinical Oncology, 21(2), 383–391. https://doi.org/10.1200/JCO.2003.02.083.PubMedCrossRef

101.

Corrado, M., Scorrano, L., & Campello, S. (2016). Changing perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agents. [Review]. Oncotarget, 7(29), 46692–46706. https://doi.org/10.18632/oncotarget.8727.PubMedPubMedCentralCrossRef

102.

Mishra, P., & Ambs, S. (2015). Metabolic signatures of human breast cancer. Molecular & Cellular Oncology, 2(3). https://doi.org/10.4161/23723556.2014.992217.

103.

von Rundstedt, F. C., Rajapakshe, K., Ma, J., Arnold, J. M., Gohlke, J., Putluri, V., et al. (2016). Integrative pathway analysis of metabolic signature in bladder cancer: a linkage to the cancer genome atlas project and prediction of survival. The Journal of Urology, 195(6), 1911–1919. https://doi.org/10.1016/j.juro.2016.01.039.CrossRef

104.

Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., et al. (2011). Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Proceedings of the National Academy of Sciences of the United States of America, 108(8), 3270–3275. https://doi.org/10.1073/pnas.1019393108. PubMedPubMedCentralCrossRef

105.

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., et al. (2010). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 465(7300), 966. https://doi.org/10.1038/nature09132.PubMedPubMedCentralCrossRef

106.

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. [Research Support, N.I.H., Extramural]. Cancer Cell, 17(3), 225–234. https://doi.org/10.1016/j.ccr.2010.01.020. PubMedPubMedCentralCrossRef

107.

Logozzi, M., De Milito, A., Lugini, L., Borghi, M., Calabro, L., Spada, M., et al. (2009). High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One, 4(4), e5219. https://doi.org/10.1371/journal.pone.0005219.PubMedPubMedCentralCrossRef

108.

Sandfeld-Paulsen, B., Aggerholm-Pedersen, N., Baek, R., Jakobsen, K. R., Meldgaard, P., Folkersen, B. H., et al. (2016). Exosomal proteins as prognostic biomarkers in non-small cell lung cancer. Molecular Oncology, 10(10), 1595–1602. https://doi.org/10.1016/j.molonc.2016.10.003.PubMedPubMedCentralCrossRef

109.

Sandfeld-Paulsen, B., Jakobsen, K. R., Baek, R., Folkersen, B. H., Rasmussen, T. R., Meldgaard, P., et al. (2016). Exosomal proteins as diagnostic biomarkers in lung cancer. Journal of Thoracic Oncology, 11(10), 1701–1710. https://doi.org/10.1016/j.jtho.2016.05.034.PubMedCrossRef

110.

Yoshioka, Y., Konishi, Y., Kosaka, N., Katsuda, T., Kato, T., & Ochiya, T. (2013). Comparative marker analysis of extracellular vesicles in different human cancer types. Journal of Extracellular Vesicles, 2. https://doi.org/10.3402/jev.v2i0.20424.

111.

Blomme, A., Fahmy, K., Peulen, O., Costanza, B., Fontaine, M., Struman, I., et al. (2016). Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes. Oncotarget, 7(50), 83669–83683. https://doi.org/10.18632/oncotarget.13276. PubMedPubMedCentralCrossRef

112.

Blomme, A., Costanza, B., de Tullio, P., Thiry, M., Van Simaeys, G., Boutry, S., et al. (2016). Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer. Oncogene. https://doi.org/10.1038/onc.2016.369.

113.

Turtoi, A., Blomme, A., Bellahcene, A., Gilles, C., Hennequiere, V., Peixoto, P., et al. (2013). Myoferlin is a key regulator of EGFR activity in breast cancer. [Research Support, Non-U.S. Gov’t]. Cancer Research, 73(17), 5438–5448. https://doi.org/10.1158/0008-5472.CAN-13-1142. PubMedCrossRef

114.

Fahmy, K., Gonzalez, A., Arafa, M., Peixoto, P., Bellahcene, A., Turtoi, A., et al. (2016). Myoferlin plays a key role in VEGFA secretion and impacts tumor-associated angiogenesis in human pancreas cancer. [Research Support, Non-U.S. Gov’t]. International Journal of Cancer, 138(3), 652–663. https://doi.org/10.1002/ijc.29820. PubMedCrossRef

115.

Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., & Lotvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. [Research Support, Non-U.S. Gov’t]. Nature Cell Biology, 9(6), 654–659. https://doi.org/10.1038/ncb1596.PubMedCrossRef

116.

Nilsson, J., Skog, J., Nordstrand, A., Baranov, V., Mincheva-Nilsson, L., Breakefield, X. O., et al. (2009). Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Validation Studies]. British Journal of Cancer, 100(10), 1603–1607. https://doi.org/10.1038/sj.bjc.6605058. PubMedPubMedCentralCrossRef

117.

Nilsson, R. J., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D. M., Walraven, M., et al. (2011). Blood platelets contain tumor-derived RNA biomarkers. [Research Support, Non-U.S. Gov’t]. Blood, 118(13), 3680–3683. https://doi.org/10.1182/blood-2011-03-344408. PubMedCrossRef

118.

Taylor, D. D., & Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Gynecologic Oncology, 110(1), 13–21. https://doi.org/10.1016/j.ygyno.2008.04.033.PubMedCrossRef

119.

Rabinowits, G., Gercel-Taylor, C., Day, J. M., Taylor, D. D., & Kloecker, G. H. (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clinical Lung Cancer, 10(1), 42–46. https://doi.org/10.3816/CLC.2009.n.006.PubMedCrossRef

120.

Haick, H., Broza, Y. Y., Mochalski, P., Ruzsanyi, V., & Amann, A. (2014). Assessment, origin, and implementation of breath volatile cancer markers. Chemical Society Reviews, 43(5), 1423–1449. https://doi.org/10.1039/c3cs60329f.PubMedCrossRef

121.

Cornu, J. N., Cancel-Tassin, G., Ondet, V., Girardet, C., & Cussenot, O. (2011). Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. European Urology, 59(2), 197–201. https://doi.org/10.1016/j.eururo.2010.10.006.PubMedCrossRef

122.

Willis, C. M., Church, S. M., Guest, C. M., Cook, W. A., McCarthy, N., Bransbury, A. J., et al. (2004). Olfactory detection of human bladder cancer by dogs: proof of principle study. BMJ, 329(7468), 712. https://doi.org/10.1136/bmj.329.7468.712.PubMedPubMedCentralCrossRef

123.

Fuchs, P., Loeseken, C., Schubert, J. K., & Miekisch, W. (2010). Breath gas aldehydes as biomarkers of lung cancer. International Journal of Cancer, 126(11), 2663–2670. https://doi.org/10.1002/ijc.24970.PubMed

124.

Song, G., Qin, T., Liu, H., Xu, G. B., Pan, Y. Y., Xiong, F. X., et al. (2010). Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer, 67(2), 227–231. https://doi.org/10.1016/j.lungcan.2009.03.029.PubMedCrossRef

125.

Wang, Y., Hu, Y., Wang, D., Yu, K., Wang, L., Zou, Y., et al. (2012). The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. Cancer Biomarkers, 11(4), 129–137. https://doi.org/10.3233/CBM-2012-00270.PubMedCrossRef

126.

Handa, H., Usuba, A., Maddula, S., Baumbach, J. I., Mineshita, M., & Miyazawa, T. (2014). Exhaled breath analysis for lung cancer detection using ion mobility spectrometry. PLoS One, 9(12), e114555. https://doi.org/10.1371/journal.pone.0114555.PubMedPubMedCentralCrossRef

127.

Zou, Y., Zhang, X., Chen, X., Hu, Y., Ying, K., & Wang, P. (2014). Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease. Cancer Biomarkers, 14(5), 371–379. https://doi.org/10.3233/CBM-140418.PubMedCrossRef

128.

Mangler, M., Freitag, C., Lanowska, M., Staeck, O., Schneider, A., & Speiser, D. (2012). Volatile organic compounds (VOCs) in exhaled breath of patients with breast cancer in a clinical setting. Ginekologia Polska, 83(10), 730–736.PubMed

129.

Qin, T., Liu, H., Song, Q., Song, G., Wang, H. Z., Pan, Y. Y., et al. (2010). The screening of volatile markers for hepatocellular carcinoma. Cancer Epidemiology, Biomarkers & Prevention, 19(9), 2247–2253. https://doi.org/10.1158/1055-9965.EPI-10-0302.CrossRef

130.

Turtoi, A., De Pauw, E., & Castronovo, V. (2011). Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies. [Research Support, Non-U.S. Gov’t Review]. The American Journal of Pathology, 178(1), 12–18. https://doi.org/10.1016/j.ajpath.2010.08.004.PubMedPubMedCentralCrossRef

131.

Dijkers, E. C., Kosterink, J. G., Rademaker, A. P., Perk, L. R., van Dongen, G. A., Bart, J., et al. (2009). Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. [Research Support, Non-U.S. Gov’t]. Journal of Nuclear Medicine, 50(6), 974–981. https://doi.org/10.2967/jnumed.108.060392. PubMedCrossRef

132.

Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., et al. (2010). Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. [Comparative Study Research Support, Non-U.S. Gov’t]. Clinical Pharmacology and Therapeutics, 87(5), 586–592. https://doi.org/10.1038/clpt.2010.12. PubMedCrossRef

133.

Orlova, A., Wallberg, H., Stone-Elander, S., & Tolmachev, V. (2009). On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. [Comparative Study Research Support, Non-U.S. Gov’t]. Journal of Nuclear Medicine, 50(3), 417–425. https://doi.org/10.2967/jnumed.108.057919.PubMedCrossRef

134.

Tolmachev, V., Velikyan, I., Sandstrom, M., & Orlova, A. (2010). A HER2-binding affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. [Comparative Study Research Support, Non-U.S. Gov’t]. European Journal of Nuclear Medicine and Molecular Imaging, 37(7), 1356–1367. https://doi.org/10.1007/s00259-009-1367-7.PubMedCrossRef

135.

Sorensen, J., Sandberg, D., Sandstrom, M., Wennborg, A., Feldwisch, J., Tolmachev, V., et al. (2014). First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, Non-U.S. Gov’t]. Journal of Nuclear Medicine, 55(5), 730–735. https://doi.org/10.2967/jnumed.113.131243. PubMedCrossRef

136.

Wu, X., Liu, H., Liu, J., Haley, K. N., Treadway, J. A., Larson, J. P., et al. (2003). Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. [Evaluation Studies Research Support, U.S. Gov't, P.H.S. Validation Studies]. Nature Biotechnology, 21(1), 41–46. https://doi.org/10.1038/nbt764. PubMedCrossRef

137.

Kaspar, M., Zardi, L., & Neri, D. (2006). Fibronectin as target for tumor therapy. [Review]. International Journal of Cancer, 118(6), 1331–1339. https://doi.org/10.1002/ijc.21677.PubMedCrossRef

138.

Neri, D., & Bicknell, R. (2005). Tumour vascular targeting. [Research Support, Non-U.S. Gov’t Review]. Nature Reviews. Cancer, 5(6), 436–446. https://doi.org/10.1038/nrc1627.PubMedCrossRef

139.

Silacci, M., Brack, S. S., Spath, N., Buck, A., Hillinger, S., Arni, S., et al. (2006). Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. [Research Support, Non-U.S. Gov’t]. Protein Engineering, Design & Selection, 19(10), 471–478. https://doi.org/10.1093/protein/gzl033. CrossRef

140.

Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.] Science, 270(5235), 467–470.PubMedCrossRef

141.

Liu, Y., & Guo, M. (2014). Chemical proteomic strategies for the discovery and development of anticancer drugs. [Research Support, Non-U.S. Gov’t Review]. Proteomics, 14(4-5), 399–411. https://doi.org/10.1002/pmic.201300261.PubMedCrossRef

142.

Rix, U., & Superti-Furga, G. (2009). Target profiling of small molecules by chemical proteomics. [Research Support, Non-U.S. Gov’t Review]. Nature Chemical Biology, 5(9), 616–624. https://doi.org/10.1038/nchembio.216.PubMedCrossRef

143.

Huang, F., Zhang, B., Zhou, S., Zhao, X., Bian, C., & Wei, Y. (2012). Chemical proteomics: terra incognita for novel drug target profiling. [Research Support, Non-U.S. Gov’t Review]. Chinese Journal of Cancer, 31(11), 507–518. https://doi.org/10.5732/cjc.011.10377.PubMedPubMedCentralCrossRef

144.

Wang, K., Yang, T., Wu, Q., Zhao, X., Nice, E. C., & Huang, C. (2012). Chemistry-based functional proteomics for drug target deconvolution. [Research Support, Non-U.S. Gov’t Review]. Expert Review of Proteomics, 9(3), 293–310. https://doi.org/10.1586/epr.12.19.PubMedCrossRef

145.

Kischel, P., Waltregny, D., & Castronovo, V. (2007). Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies. [Research Support, Non-U.S. Gov’t Review]. Expert Review of Proteomics, 4(6), 727–739. https://doi.org/10.1586/14789450.4.6.727.PubMedCrossRef

146.

Rybak, J. N., Ettorre, A., Kaissling, B., Giavazzi, R., Neri, D., & Elia, G. (2005). In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. [Evaluation Studies Research Support, Non-U.S. Gov’t]. Nature Methods, 2(4), 291–298. https://doi.org/10.1038/nmeth745.PubMedCrossRef

147.

Roesli, C., Neri, D., & Rybak, J. N. (2006). In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. [Research Support, Non-U.S. Gov’t]. Nature Protocols, 1(1), 192–199. https://doi.org/10.1038/nprot.2006.29.PubMedCrossRef

148.

Castronovo, V., Kischel, P., Guillonneau, F., de Leval, L., Defechereux, T., De Pauw, E., et al. (2007). Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. [Evaluation Studies Research Support, Non-U.S. Gov’t]. Proteomics, 7(8), 1188–1196. https://doi.org/10.1002/pmic.200600888. PubMedCrossRef

149.

Castronovo, V., Waltregny, D., Kischel, P., Roesli, C., Elia, G., Rybak, J. N., et al. (2006). A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. [Research Support, Non-U.S. Gov’t]. Molecular & Cellular Proteomics, 5(11), 2083–2091. https://doi.org/10.1074/mcp.M600164-MCP200. CrossRef

150.

Turtoi, A., Dumont, B., Greffe, Y., Blomme, A., Mazzucchelli, G., Delvenne, P., et al. (2011). Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues. [Research Support, Non-U.S. Gov’t]. Journal of Proteome Research, 10(7), 3160–3182. https://doi.org/10.1021/pr200212r. PubMedCrossRef

151.

Turtoi, A., Musmeci, D., Wang, Y., Dumont, B., Somja, J., Bevilacqua, G., et al. (2011). Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. [Research Support, Non-U.S. Gov’t]. Journal of Proteome Research, 10(9), 4302–4313. https://doi.org/10.1021/pr200527z. PubMedCrossRef

152.

Conrotto, P., Roesli, C., Rybak, J., Kischel, P., Waltregny, D., Neri, D., et al. (2008). Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. [Comparative Study Research Support, Non-U.S. Gov’t]. International Journal of Cancer, 123(12), 2856–2864. https://doi.org/10.1002/ijc.23861. PubMedCrossRef

153.

Borgia, B., Roesli, C., Fugmann, T., Schliemann, C., Cesca, M., Neri, D., et al. (2010). A proteomic approach for the identification of vascular markers of liver metastasis. [Research Support, Non-U.S. Gov’t]. Cancer Research, 70(1), 309–318. https://doi.org/10.1158/0008-5472.CAN-09-2939. PubMedCrossRef

154.

Schliemann, C., Roesli, C., Kamada, H., Borgia, B., Fugmann, T., Klapper, W., et al. (2010). In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. [Evaluation Studies Research Support, Non-U.S. Gov’t]. Blood, 115(3), 736–744. https://doi.org/10.1182/blood-2009-08-239004. PubMedCrossRef

155.

Wollscheid, B., Bausch-Fluck, D., Henderson, C., O'Brien, R., Bibel, M., Schiess, R., et al. (2009). Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nature Biotechnology, 27(4), 378–386. https://doi.org/10.1038/nbt.1532. PubMedPubMedCentralCrossRef

156.

Zhang, H., Li, X. J., Martin, D. B., & Aebersold, R. (2003). Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. [Evaluation Studies Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. Validation Studies]. Nature Biotechnology, 21(6), 660–666. https://doi.org/10.1038/nbt827.PubMedCrossRef

157.

Tian, Y., Zhou, Y., Elliott, S., Aebersold, R., & Zhang, H. (2007). Solid-phase extraction of N-linked glycopeptides. [Research Support, N.I.H., Extramural]. Nature Protocols, 2(2), 334–339. https://doi.org/10.1038/nprot.2007.42.PubMedPubMedCentralCrossRef

158.

Celis, J. E., Gromov, P., Cabezon, T., Moreira, J. M., Ambartsumian, N., Sandelin, K., et al. (2004). Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Molecular & Cellular Proteomics, 3(4), 327–344. https://doi.org/10.1074/mcp.M400009-MCP200.CrossRef

159.

Fijneman, R. J., de Wit, M., Pourghiasian, M., Piersma, S. R., Pham, T. V., Warmoes, M. O., et al. (2012). Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clinical Cancer Research, 18(9), 2613–2624. https://doi.org/10.1158/1078-0432.CCR-11-1937.PubMedCrossRef

160.

de Wit, M., Fijneman, R. J., Verheul, H. M., Meijer, G. A., & Jimenez, C. R. (2013). Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clinical Biochemistry, 46(6), 466–479. https://doi.org/10.1016/j.clinbiochem.2012.10.039.PubMedCrossRef

161.

de Wit, M., Kant, H., Piersma, S. R., Pham, T. V., Mongera, S., van Berkel, M. P., et al. (2014). Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. [Clinical Trial Research Support, Non-U.S. Gov’t]. Journal of Proteomics, 99, 26–39. https://doi.org/10.1016/j.jprot.2014.01.001. PubMedCrossRef

162.

Raso, C., Cosentino, C., Gaspari, M., Malara, N., Han, X., McClatchy, D., et al. (2012). Characterization of breast cancer interstitial fluids by TmT labeling, LTQ-Orbitrap Velos mass spectrometry, and pathway analysis. Journal of Proteome Research, 11(6), 3199–3210. https://doi.org/10.1021/pr2012347.PubMedCrossRef

163.

Teng, P. N., Hood, B. L., Sun, M., Dhir, R., & Conrads, T. P. (2011). Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. [Evaluation Studies Research Support, Non-U.S. Gov’t]. Journal of Proteome Research, 10(3), 1333–1342. https://doi.org/10.1021/pr101074p.PubMedCrossRef

164.

Dabrosin, C. (2005). Microdialysis—an in vivo technique for studies of growth factors in breast cancer. Frontiers in Bioscience, 10, 1329–1335.PubMedCrossRef

165.

Huang, C. M., Nakatsuji, T., Liu, Y. T., & Shi, Y. (2008). In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome. Recent Patents on Anti-Cancer Drug Discovery, 3(1), 48–54.PubMedPubMedCentralCrossRef

166.

Huang, C. M., Ananthaswamy, H. N., Barnes, S., Ma, Y., Kawai, M., & Elmets, C. A. (2006). Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics, 6(22), 6107–6116. https://doi.org/10.1002/pmic.200600287.PubMedCrossRef

167.

Wiig, H., Aukland, K., & Tenstad, O. (2003). Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. American Journal of Physiology. Heart and Circulatory Physiology, 284(1), H416–H424. https://doi.org/10.1152/ajpheart.00327.2002.PubMedCrossRef

168.

Haslene-Hox, H., Tenstad, O., & Wiig, H. (2013). Interstitial fluid-a reflection of the tumor cell microenvironment and secretome. Biochimica et Biophysica Acta, 1834(11), 2336–2346. https://doi.org/10.1016/j.bbapap.2013.01.028.PubMedCrossRef

169.

Hoskins, E. R., Hood, B. L., Sun, M., Krivak, T. C., Edwards, R. P., & Conrads, T. P. (2011). Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. [Research Support, Non-U.S. Gov’t]. PLoS One, 6(9), e25056. https://doi.org/10.1371/journal.pone.0025056.PubMedPubMedCentralCrossRef

170.

Sun, W., Ma, J., Wu, S., Yang, D., Yan, Y., Liu, K., et al. (2010). Characterization of the liver tissue interstitial fluid (TIF) proteome indicates potential for application in liver disease biomarker discovery. Journal of Proteome Research, 9(2), 1020–1031. https://doi.org/10.1021/pr9009172.PubMedCrossRef

171.

Gromov, P., Gromova, I., Bunkenborg, J., Cabezon, T., Moreira, J. M., Timmermans-Wielenga, V., et al. (2010). Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Molecular Oncology, 4(1), 65–89. https://doi.org/10.1016/j.molonc.2009.11.003.PubMedCrossRef

172.

Wang, Y., Shan, Q., Hou, G., Zhang, J., Bai, J., Lv, X., et al. (2016). Discovery of potential colorectal cancer serum biomarkers through quantitative proteomics on the colonic tissue interstitial fluids from the AOM-DSS mouse model. Journal of Proteomics, 132, 31–40. https://doi.org/10.1016/j.jprot.2015.11.013.PubMedCrossRef

173.

Huminiecki, L., & Bicknell, R. (2000). In silico cloning of novel endothelial-specific genes. [Comparative Study]. Genome Research, 10(11), 1796–1806.PubMedPubMedCentralCrossRef

174.

Jensen, L. J., Kuhn, M., Stark, M., Chaffron, S., Creevey, C., Muller, J., et al. (2009). STRING 8—a global view on proteins and their functional interactions in 630 organisms. [Research Support, Non-U.S. Gov’t]. Nucleic Acids Research, 37(Database issue), D412–D416. https://doi.org/10.1093/nar/gkn760.PubMedCrossRef

175.

Fugmann, T., Neri, D., & Roesli, C. (2010). DeepQuanTR: MALDI-MS-based label-free quantification of proteins in complex biological samples. [Research Support, Non-U.S. Gov’t]. Proteomics, 10(14), 2631–2643. https://doi.org/10.1002/pmic.200900634.PubMedCrossRef

176.

Hassan, S., Ferrario, C., Mamo, A., & Basik, M. (2008). Tissue microarrays: emerging standard for biomarker validation. [Review Validation Studies]. Current Opinion in Biotechnology, 19(1), 19–25. https://doi.org/10.1016/j.copbio.2007.10.009.PubMedCrossRef

177.

Camp, R. L., Neumeister, V., & Rimm, D. L. (2008). A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. [Review]. Journal of Clinical Oncology, 26(34), 5630–5637. https://doi.org/10.1200/JCO.2008.17.3567.PubMedCrossRef

178.

Schoenberg Fejzo, M., & Slamon, D. J. (2001). Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. [Research Support, Non-U.S. Gov’t]. The American Journal of Pathology, 159(5), 1645–1650. https://doi.org/10.1016/S0002-9440(10)63011-8.PubMedPubMedCentralCrossRef

179.

Datta, M. W., Kahler, A., Macias, V., Brodzeller, T., & Kajdacsy-Balla, A. (2005). A simple inexpensive method for the production of tissue microarrays from needle biopsy specimens: examples with prostate cancer. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] Applied Immunohistochemistry & Molecular Morphology, 13(1), 96–103.CrossRef

180.

Parker, C. E., & Borchers, C. H. (2014). Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays. [Research Support, Non-U.S. Gov’t Review]. Molecular Oncology, 8(4), 840–858. https://doi.org/10.1016/j.molonc.2014.03.006.PubMedPubMedCentralCrossRef

181.

Rifai, N., Gillette, M. A., & Carr, S. A. (2006). Protein biomarker discovery and validation: the long and uncertain path to clinical utility. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Nature Biotechnology, 24(8), 971–983. https://doi.org/10.1038/nbt1235.PubMedCrossRef

182.

Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B., Olafson, R. W., & Pearson, T. W. (2004). Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). [Research Support, Non-U.S. Gov’t]. Journal of Proteome Research, 3(2), 235–244.PubMedCrossRef

183.

Whiteaker, J. R., Zhao, L., Zhang, H. Y., Feng, L. C., Piening, B. D., Anderson, L., et al. (2007). Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Analytical Biochemistry, 362(1), 44–54. https://doi.org/10.1016/j.ab.2006.12.023. PubMedCrossRef

184.

Malou, N., & Raoult, D. (2011). Immuno-PCR: a promising ultrasensitive diagnostic method to detect antigens and antibodies. [Evaluation Studies Review]. Trends in Microbiology, 19(6), 295–302. https://doi.org/10.1016/j.tim.2011.03.004.PubMedCrossRef

185.

Dasilva, N., Diez, P., Matarraz, S., Gonzalez-Gonzalez, M., Paradinas, S., Orfao, A., et al. (2012). Biomarker discovery by novel sensors based on nanoproteomics approaches. [Research Support, Non-U.S. Gov’t Review]. Sensors (Basel), 12(2), 2284–2308. https://doi.org/10.3390/s120202284. CrossRef

186.

Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.] Nature Biotechnology, 17(10), 994–999. https://doi.org/10.1038/13690.PubMedCrossRef

187.

Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., et al. (2004). Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] Nature, 429(6992), 629–635. https://doi.org/10.1038/nature02580.PubMedCrossRef

188.

Pasqualini, R., & Ruoslahti, E. (1996). Organ targeting in vivo using phage display peptide libraries. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] Nature, 380(6572), 364–366. https://doi.org/10.1038/380364a0.PubMedCrossRef

189.

Weigl, B. H., Bardell, R. L., & Cabrera, C. R. (2003). Lab-on-a-chip for drug development. [Review]. Advanced Drug Delivery Reviews, 55(3), 349–377.PubMedCrossRef

190.

Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., et al. (2011). NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. Journal of the National Comprehensive Cancer Network, 9(Suppl 5), S1–32 quiz S33.CrossRef

191.

Jamal-Hanjani, M., Quezada, S. A., Larkin, J., & Swanton, C. (2015). Translational implications of tumor heterogeneity. [Research Support, Non-U.S. Gov’t Review]. Clinical Cancer Research, 21(6), 1258–1266. https://doi.org/10.1158/1078-0432.CCR-14-1429.PubMedPubMedCentralCrossRef

192.

Espina, V., Wulfkuhle, J. D., Calvert, V. S., VanMeter, A., Zhou, W., Coukos, G., et al. (2006). Laser-capture microdissection. Nature Protocols, 1(2), 586–603. https://doi.org/10.1038/nprot.2006.85.PubMedCrossRef

193.

Baker, H., Patel, V., Molinolo, A. A., Shillitoe, E. J., Ensley, J. F., Yoo, G. H., et al. (2005). Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncology, 41(2), 183–199. https://doi.org/10.1016/j.oraloncology.2004.08.009.PubMedCrossRef

194.

Li, C., Hong, Y., Tan, Y. X., Zhou, H., Ai, J. H., Li, S. J., et al. (2004). Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. [Comparative Study Research Support, Non-U.S. Gov’t]. Molecular & Cellular Proteomics, 3(4), 399–409. https://doi.org/10.1074/mcp.M300133-MCP200. CrossRef

195.

Dirks, R. A., Stunnenberg, H. G., & Marks, H. (2016). Genome-wide epigenomic profiling for biomarker discovery. [Review]. Clinical Epigenetics, 8, 122. https://doi.org/10.1186/s13148-016-0284-4.PubMedPubMedCentralCrossRef

196.

Anderson, N. L., & Anderson, N. G. (2002). The human plasma proteome: history, character, and diagnostic prospects. Molecular & Cellular Proteomics, 1(11), 845–867.CrossRef

197.

States, D. J., Omenn, G. S., Blackwell, T. W., Fermin, D., Eng, J., Speicher, D. W., et al. (2006). Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nature Biotechnology, 24(3), 333–338. https://doi.org/10.1038/nbt1183. PubMedCrossRef

198.

Jacobs, J. M., Adkins, J. N., Qian, W. J., Liu, T., Shen, Y., Camp 2nd, D. G., et al. (2005). Utilizing human blood plasma for proteomic biomarker discovery. [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S. Review]. Journal of Proteome Research, 4(4), 1073–1085. https://doi.org/10.1021/pr0500657. PubMedCrossRef

199.

Bodzon-Kulakowska, A., Bierczynska-Krzysik, A., Dylag, T., Drabik, A., Suder, P., Noga, M., et al. (2007). Methods for samples preparation in proteomic research. [Research Support, Non-U.S. Gov’t Review]. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 849(1-2), 1–31. https://doi.org/10.1016/j.jchromb.2006.10.040. PubMedCrossRef

200.

Feist, P., & Hummon, A. B. (2015). Proteomic challenges: sample preparation techniques for microgram-quantity protein analysis from biological samples. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Review]. International Journal of Molecular Sciences, 16(2), 3537–3563. https://doi.org/10.3390/ijms16023537.PubMedPubMedCentralCrossRef

201.

Bodovitz, S., & Joos, T. (2004). The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets. [Evaluation Studies Validation Studies]. Trends in Biotechnology, 22(1), 4–7. https://doi.org/10.1016/j.tibtech.2003.10.013.PubMedCrossRef

202.

Anderson, R., O'Hare, M., Balls, M., Brady, M., Brahams, D., Burt, A., et al. (1998). The availability of human tissue for biomedical research: the Report and Recommendations of the ECVAM Workshop 32. [Guideline]. Alternatives to Laboratory Animals, 26(6), 763–777.PubMed

203.

Riondino, S., Ferroni, P., Spila, A., Alessandroni, J., D’Alessandro, R., Formica, V., et al. (2015). Ensuring sample quality for biomarker discovery studies—use of ICT tools to trace biosample life-cycle. [Research Support, Non-U.S. Gov’t Review]. Cancer Genomics Proteomics, 12(6), 291–299.PubMed

204.

Zehetmayer, S., Bauer, P., & Posch, M. (2005). Two-stage designs for experiments with a large number of hypotheses. [Evaluation Studies Research Support, Non-U.S. Gov’t]. Bioinformatics, 21(19), 3771–3777. https://doi.org/10.1093/bioinformatics/bti604.PubMedCrossRef

205.

Wallstrom, G., Anderson, K. S., & LaBaer, J. (2013). Biomarker discovery for heterogeneous diseases. Cancer Epidemiology, Biomarkers & Prevention, 22(5), 747–755. https://doi.org/10.1158/1055-9965.EPI-12-1236.CrossRef

206.

Hiley, C., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014). Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. [Research Support, Non-U.S. Gov’t Review]. Genome Biology, 15(8), 453. https://doi.org/10.1186/s13059-014-0453-8.PubMedPubMedCentralCrossRef

207.

Jamal-Hanjani, M., Hackshaw, A., Ngai, Y., Shaw, J., Dive, C., Quezada, S., et al. (2014). Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. [Research Support, Non-U.S. Gov’t]. PLoS Biology, 12(7), e1001906. https://doi.org/10.1371/journal.pbio.1001906. PubMedPubMedCentralCrossRef

208.

Kucherlapati, R. (2012). Genetically modified mouse models for biomarker discovery and preclinical drug testing. [Research Support, N.I.H., Extramural]. Clinical Cancer Research, 18(3), 625–630. https://doi.org/10.1158/1078-0432.CCR-11-2021. PubMedCrossRef

209.

Kelly-Spratt, K. S., Kasarda, A. E., Igra, M., & Kemp, C. J. (2008). A mouse model repository for cancer biomarker discovery. Journal of Proteome Research, 7(8), 3613–3618. https://doi.org/10.1021/pr800210b.PubMedPubMedCentralCrossRef

210.

Zhang, H., Yi, E. C., Li, X. J., Mallick, P., Kelly-Spratt, K. S., Masselon, C. D., et al. (2005). High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.] Molecular & Cellular Proteomics, 4(2), 144–155. https://doi.org/10.1074/mcp.M400090-MCP200. CrossRef

211.

Whiteaker, J. R., Zhang, H., Zhao, L., Wang, P., Kelly-Spratt, K. S., Ivey, R. G., et al. (2007). Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of Proteome Research, 6(10), 3962–3975. https://doi.org/10.1021/pr070202v. PubMedCrossRef

212.

Siolas, D., & Hannon, G. J. (2013). Patient-derived tumor xenografts: transforming clinical samples into mouse models. [Review]. Cancer Research, 73(17), 5315–5319. https://doi.org/10.1158/0008-5472.CAN-13-1069.PubMedPubMedCentralCrossRef

213.

Pitts, T. M., Tan, A. C., Kulikowski, G. N., Tentler, J. J., Brown, A. M., Flanigan, S. A., et al. (2010). Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Clinical Cancer Research, 16(12), 3193–3204. https://doi.org/10.1158/1078-0432.CCR-09-3191. PubMedPubMedCentralCrossRef

214.

Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., et al. (2012). Patient-derived tumour xenografts as models for oncology drug development. [Review]. Nature Reviews. Clinical Oncology, 9(6), 338–350. https://doi.org/10.1038/nrclinonc.2012.61. PubMedPubMedCentralCrossRef

215.

Weroha, S. J., Becker, M. A., Enderica-Gonzalez, S., Harrington, S. C., Oberg, A. L., Maurer, M. J., et al. (2014). Tumorgrafts as in vivo surrogates for women with ovarian cancer. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Clinical Cancer Research, 20(5), 1288–1297. https://doi.org/10.1158/1078-0432.CCR-13-2611. PubMedPubMedCentralCrossRef

216.

Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., et al. (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular Cancer Therapeutics, 10(8), 1311–1316. https://doi.org/10.1158/1535-7163.MCT-11-0233.PubMedPubMedCentralCrossRef

217.

Denayer, T., Stohr, T., & Van Roy, M. (2014). Animal models in translational medicine: validation and prediction. New Horizons in Translational Medicine, 2(1), 5–11. https://doi.org/10.1016/j.nhtm.2014.08.001.CrossRef

218.

Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., & Greiner, D. L. (2012). Humanized mice for immune system investigation: progress, promise and challenges. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Nature Reviews. Immunology, 12(11), 786–798. https://doi.org/10.1038/nri3311.PubMedPubMedCentralCrossRef

219.

Zhou, Q., Facciponte, J., Jin, M., Shen, Q., & Lin, Q. (2014). Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. [Review]. Cancer Letters, 344(1), 13–19. https://doi.org/10.1016/j.canlet.2013.10.015.PubMedCrossRef

220.

Tu, C., Rudnick, P. A., Martinez, M. Y., Cheek, K. L., Stein, S. E., Slebos, R. J., et al. (2010). Depletion of abundant plasma proteins and limitations of plasma proteomics. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of Proteome Research, 9(10), 4982–4991. https://doi.org/10.1021/pr100646w. PubMedPubMedCentralCrossRef

221.

Wilkins, M. R., Appel, R. D., Van Eyk, J. E., Chung, M. C., Gorg, A., Hecker, M., et al. (2006). Guidelines for the next 10 years of proteomics. Proteomics, 6(1), 4–8. https://doi.org/10.1002/pmic.200500856.PubMedCrossRef

222.

Righetti, P. G., Boschetti, E., Lomas, L., & Citterio, A. (2006). Protein equalizer technology: the quest for a “democratic proteome”. [Research Support, Non-U.S. Gov’t Review]. Proteomics, 6(14), 3980–3992. https://doi.org/10.1002/pmic.200500904.PubMedCrossRef

223.

Adam, G. C., Sorensen, E. J., & Cravatt, B. F. (2002). Chemical strategies for functional proteomics. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. Review]. Molecular & Cellular Proteomics, 1(10), 781–790.CrossRef

224.

Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013). Tumour heterogeneity in the clinic. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nature, 501(7467), 355–364. https://doi.org/10.1038/nature12627.PubMedPubMedCentralCrossRef

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Mutations of key driver genes in colorectal cancer progression and metastasis

Non-coding RNAs, epigenetics, and cancer: tying it all together

Preface

MiR-181 family-specific behavior in different cancers: a meta-analysis view